VEGFA and glaucoma: An explanation for this fact and elevated IOP levels in glaucoma patients after anti-VEGF injections in general could be that high molecular weight proteins, such as bevacizumab (150 kDa), which is approximately three times larger than ranibizumab may obstruct in the outflow and accumulate in the trabecular meshwork [30].